ATyr Pharma Company Insiders

ATyr Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.4959) % which means that it has lost $0.4959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0349) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma's management efficiency ratios could be used to measure how well ATyr Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/08/2026, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, ATyr Pharma's Non Currrent Assets Other are relatively stable compared to the past year. As of 01/08/2026, Other Current Assets is likely to grow to about 9.8 M, while Non Current Assets Total are likely to drop slightly above 9.2 M. As of 01/08/2026, Common Stock Shares Outstanding is likely to grow to about 89.7 MATyr Pharma holds a total of 97.99 Million outstanding shares. Over half of ATyr Pharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as ATyr Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of ATyr Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

ATyr Pharma Workforce Comparison

ATyr Pharma Insider Trading

ATyr Pharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as aTyr Pharma often depends on how effective the management is. ATyr Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ATyr management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ATyr management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.